Merck Recalls Cholesterol Drug Liptruzet

Company issues recall due to defects in product packaging

TUESDAY, Jan. 14, 2014 (HealthDay News) -- Packaging defects have prompted a recall of the combination cholesterol drug Liptruzet, produced by Merck & Co., temporarily affecting the entire U.S. stock.

Merck said the foil pouches holding Liptruzet pills could allow air and moisture inside, potentially decreasing the drug's effectiveness. The recall covers all four dose strengths and every batch that's gone out since Liptruzet hit the market in May.

Liptruzet combines atorvastatin and Zetia (ezetimibe). Cardiologists expect no health problems to result from the recall, in part because both atorvastatin and Zetia will remain available separately.

"Patients are not going to be in any harm's way just going on atorvastatin until this packaging issue gets corrected," Kevin Marzo, M.D., chief of cardiology at Winthrop-University Hospital in Mineola, N.Y., told HealthDay.

Full Article

Copyright © 2014 HealthDay. All rights reserved.

Powered by

Featured Jobs



Benefits of Membership

FREE E-Newsletters
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues

CESaver
Join our CESaver program to earn up to 100 contact hours for only $34.95
Register Now

Lippincott's NursingCenter.com
Explore a world of online resources

Become a Member